This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Companies in this article
Catalent Pharma Solutions, a leading provider of drug and biologic development services, delivery technologies and supply solutions, announced that it has entered into an agreement with Nuron Biotech for the formulation and supply of NU100 (interferon beta-1b), a proprietary recombinant human interferon beta compound being developed for the treatment of multiple sclerosis (MS).
This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.